Psychopharmacology and Psychiatry Updates

In this episode, we explore whether we can predict which bipolar disorder treatments will work for specific patients before months of trial and error. Could your patient's clinical profile, family history, or even their own neurons hold the key to finding the right medication sooner?
Faculty: Kristin Raj, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.5 CMEs: Quick Take Vol. 81
Can We Predict Who Responds to Mood Stabilizers?

In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-making in treatment planning.
Faculty: Brian Miller, M.D., Ph.D., M.P.H.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Understanding When to Prescribe LAIs

In this episode, we explore a striking new Nature study suggesting that lithium deficiency may play a central role in the onset of Alzheimer's disease. Could a simple, overlooked supplement be the key to prevention? Dr. Scott Beach unpacks the science, the promise, and the important caveats.
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.5 CME: Quick Take Vol. 81
Lithium Orotate: Breakthrough Treatment for Alzheimer's Disease?

In this episode, we explore the nuanced challenge of managing ADHD with stimulant medications during pregnancy. Is stopping the medication always the safer choice — or does untreated ADHD carry risks of its own? Dr. Amanda Koire breaks down the latest evidence to help clinicians make truly informed decisions.
Faculty: Amanda Koire, M.D., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know
Pregnancy, ADHD, and Stimulants: Making an Informed Choice

In this episode, we examine a surprising repurposing of ondansetron — a common antiemetic — as a potential adjunctive treatment for the notoriously hard-to-treat negative symptoms of schizophrenia. Could a nausea medication help restore motivation and emotional engagement in your patients with residual symptoms despite stable antipsychotic therapy?
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.5 CMEs: Quick Take Vol. 81
Is Ondansetron Effective for Negative Symptoms in Schizophrenia?